-
1
-
-
0036484856
-
Chronic inflammation and cancer
-
discussion 230-2
-
Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002;16:217-26, 229; discussion 230-2.
-
(2002)
Oncology
, vol.16
-
-
Shacter, E.1
Weitzman, S.A.2
-
2
-
-
44349093644
-
Cancer in rheumatoid arthritis: Occurrence, mortality, and associated factors in a South European population
-
Abasolo L, Judez E, Descalzo MA et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-97.
-
(2008)
Semin Arthritis Rheum
, vol.37
, pp. 388-397
-
-
Abasolo, L.1
Judez, E.2
Descalzo, M.A.3
-
3
-
-
84939167646
-
Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis
-
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212.
-
(2015)
Arthritis Res Ther
, vol.17
, pp. 212
-
-
Simon, T.A.1
Thompson, A.2
Gandhi, K.K.3
Hochberg, M.C.4
Suissa, S.5
-
4
-
-
2642554059
-
Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients
-
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1740-1751
-
-
Wolfe, F.1
Michaud, K.2
-
5
-
-
67549122368
-
Etanercept therapy in rheumatoid arthritis and the risk of malignancies: A systematic review and individual patient data meta-analysis of randomised controlled trials
-
Bongartz T, Warren FC, Mines D et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1177-1183
-
-
Bongartz, T.1
Warren, F.C.2
Mines, D.3
-
6
-
-
67549117204
-
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
-
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1136-1145
-
-
Leombruno, J.P.1
Einarson, T.R.2
Keystone, E.C.3
-
7
-
-
27744527575
-
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
-
Askling J, Fored CM, Brandt L et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1421-1426
-
-
Askling, J.1
Fored, C.M.2
Brandt, L.3
-
8
-
-
84860915531
-
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register
-
Mercer LK, Green AC, Galloway JB et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 869-874
-
-
Mercer, L.K.1
Green, A.C.2
Galloway, J.B.3
-
9
-
-
84877633711
-
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden
-
Raaschou P, Simard JF, Holmqvist M, Askling J, Group AS. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939.
-
(2013)
BMJ
, vol.346
, pp. f1939
-
-
Raaschou, P.1
Simard, J.F.2
Holmqvist, M.3
Askling, J.4
Group, A.S.5
-
10
-
-
77953103015
-
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register
-
Dixon WG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010;62:755-63.
-
(2010)
Arthritis Care Res
, vol.62
, pp. 755-763
-
-
Dixon, W.G.1
Watson, K.D.2
Lunt, M.3
-
11
-
-
77955479672
-
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
-
Strangfeld A, Hierse F, Rau R et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
-
(2010)
Arthritis Res Ther
, vol.12
, pp. R5
-
-
Strangfeld, A.1
Hierse, F.2
Rau, R.3
-
12
-
-
0032530342
-
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
-
Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
-
(1998)
Blood
, vol.92
, pp. 1927-1932
-
-
Coiffier, B.1
Haioun, C.2
Ketterer, N.3
-
13
-
-
66149084485
-
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register
-
Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-53.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 648-653
-
-
Askling, J.1
Baecklund, E.2
Granath, F.3
-
14
-
-
84865692521
-
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis
-
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
-
(2012)
JAMA
, vol.308
, pp. 898-908
-
-
Lopez-Olivo, M.A.1
Tayar, J.H.2
Martinez-Lopez, J.A.3
-
15
-
-
52949084362
-
The British Society for Rheumatology Biologics Register: 6 years on
-
Hyrich KL, Watson KD, Isenberg DA, Symmons DP, Register BSRB. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
-
(2008)
Rheumatology
, vol.47
, pp. 1441-1443
-
-
Hyrich, K.L.1
Watson, K.D.2
Isenberg, D.A.3
Symmons, D.P.4
Register, B.S.R.B.5
-
16
-
-
84871127807
-
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
-
Mercer LK, Davies R, Galloway JB et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013;52:91-8.
-
(2013)
Rheumatology
, vol.52
, pp. 91-98
-
-
Mercer, L.K.1
Davies, R.2
Galloway, J.B.3
-
17
-
-
84932606892
-
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
-
Mercer LK, Lunt M, Low AL et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;74:1087-93.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 1087-1093
-
-
Mercer, L.K.1
Lunt, M.2
Low, A.L.3
-
18
-
-
33644892763
-
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
-
Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 692-701
-
-
Baecklund, E.1
Iliadou, A.2
Askling, J.3
-
19
-
-
33845342915
-
Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics
-
Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77.
-
(2006)
Cancer Epidemiol Biomarkers Prev
, vol.15
, pp. 2069-2077
-
-
Smedby, K.E.1
Baecklund, E.2
Askling, J.3
-
20
-
-
70349464351
-
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
-
Hyrich KL, Deighton C, Watson KD et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology 2009;48:1323-7.
-
(2009)
Rheumatology
, vol.48
, pp. 1323-1327
-
-
Hyrich, K.L.1
Deighton, C.2
Watson, K.D.3
-
21
-
-
84856548244
-
Effectiveness of rituximab in patients with rheumatoid arthritis: Observational study from the British Society for Rheumatology Biologics Register
-
Soliman MM, Hyrich KL, Lunt M et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012;39:240-6.
-
(2012)
J Rheumatol
, vol.39
, pp. 240-246
-
-
Soliman, M.M.1
Hyrich, K.L.2
Lunt, M.3
|